| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three and six months ended May 31, 2026 and 2025:
|
|
|
|
|
|
|
|
|
|
|
For the three months ended May 31, |
|
|
|
2026 |
|
|
2025 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
7,715,446 |
|
|
$ |
7,871,719 |
|
PrepaCyte CB |
|
|
14,182 |
|
|
|
14,436 |
|
Public cord blood banking |
|
|
46,485 |
|
|
|
42,688 |
|
Total net revenue |
|
$ |
7,776,113 |
|
|
$ |
7,928,843 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,554,459 |
|
|
$ |
1,652,108 |
|
PrepaCyte CB |
|
|
5,783 |
|
|
|
4,283 |
|
Public cord blood banking |
|
|
116,421 |
|
|
|
200,148 |
|
Total cost of sales |
|
$ |
1,676,663 |
|
|
$ |
1,856,539 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,259,127 |
|
|
$ |
1,646,885 |
|
PrepaCyte CB |
|
|
8,150 |
|
|
|
3,209 |
|
Public cord blood banking |
|
|
(69,936 |
) |
|
|
(157,460 |
) |
Total operating profit |
|
$ |
1,197,341 |
|
|
$ |
1,492,634 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
184,080 |
|
|
$ |
183,158 |
|
PrepaCyte CB |
|
|
249 |
|
|
|
6,944 |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total depreciation and amortization |
|
$ |
184,329 |
|
|
$ |
190,102 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
441,917 |
|
|
$ |
551,126 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
441,917 |
|
|
$ |
551,126 |
|
|
|
|
|
|
|
|
|
|
For the six months ended May 31, |
|
|
|
2026 |
|
|
2025 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
15,358,559 |
|
|
$ |
15,737,607 |
|
PrepaCyte CB |
|
|
52,776 |
|
|
|
35,349 |
|
Public cord blood banking |
|
|
47,895 |
|
|
|
124,767 |
|
Total net revenue |
|
$ |
15,459,230 |
|
|
$ |
15,897,723 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
3,098,460 |
|
|
$ |
3,353,743 |
|
PrepaCyte CB |
|
|
17,970 |
|
|
|
11,242 |
|
Public cord blood banking |
|
|
216,721 |
|
|
|
476,142 |
|
Total cost of sales |
|
$ |
3,333,151 |
|
|
$ |
3,841,127 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
2,096,992 |
|
|
$ |
2,889,802 |
|
PrepaCyte CB |
|
|
34,309 |
|
|
|
10,218 |
|
Public cord blood banking |
|
|
(168,826 |
) |
|
|
(351,375 |
) |
Total operating profit |
|
$ |
1,962,475 |
|
|
$ |
2,548,645 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
367,719 |
|
|
$ |
368,066 |
|
PrepaCyte CB |
|
|
497 |
|
|
|
13,889 |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total depreciation and amortization |
|
$ |
368,216 |
|
|
$ |
381,955 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
904,626 |
|
|
$ |
1,046,088 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
904,626 |
|
|
$ |
1,046,088 |
|
The following table shows the assets by segment as of May 31, 2026 and November 30, 2025:
|
|
|
|
|
|
|
|
|
|
|
As of |
|
|
As of |
|
|
|
May 31, 2026 |
|
|
November 30, 2025 |
|
Assets: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell
service |
|
$ |
59,799,263 |
|
|
$ |
60,788,322 |
|
PrepaCyte CB |
|
|
122,149 |
|
|
|
135,379 |
|
Public cord blood banking |
|
|
785,018 |
|
|
|
804,813 |
|
Total assets |
|
$ |
60,706,430 |
|
|
$ |
61,728,514 |
|
|